Septerna, Inc.
SEPN Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$44.14
KIRA · Stoqly’s AI analyst, in plain words
- Septerna, Inc. had $46.0M of revenue in fiscal 2025, up 4,174.5% on the year before.
- Its operating margin was −148.6%, up 7,369.8 pts: of every 100 in sales, about −149 is left after running the business.
- Septerna, Inc. lost $48.9M in fiscal 2025.
- Free cash flow was $110M in fiscal 2025, 238.7% of revenue.
Market cap
$2.0B
P/E
—
Revenue
$46.0M
Net income
−$48.9M
Free cash flow
$110M
Operating margin
−148.6%
Septerna, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+4,174.5%
Yes. Sales grew 4,174.5% last year.
Does it make a profit?
−106.4%
No. It lost money last year.
Does profit turn into cash?
238.7%
Yes. 238.7% of sales ends up as free cash.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Septerna, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- Septerna, Inc.
- CIK
- 0001984086
Septerna, Inc. · SEPN
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $0.2M | $1.1M | $46.0M |
| Revenue growth | — | 611.9% | 4,174.5% |
| Operating margin | 1,374.2% | −7,518.4% | −148.6% |
| Net income | $4.2M | −$71.8M | −$48.9M |
| Net margin | 2,768.2% | −6,678.9% | −106.4% |
| Diluted EPS | $0.29 | −$7.26 | −$1.10 |
| Cash | |||
| Cash from operations | −$38.7M | −$67.5M | $110M |
| Capital expenditure | $2.9M | $2.1M | $0.5M |
| Free cash flow | −$41.6M | −$69.6M | $110M |
| FCF margin | −27,550.3% | −6,471.9% | 238.7% |
| Share count change | — | 354.3% | 347.5% |
| Debt and strength | |||
| Cash and short-term investments | $88.5M | $351M | $391M |
| Shareholders' equity | −$38.4M | $420M | $382M |
| Current ratio | 16.3x | 27.8x | 4.7x |
| Returns and quality | |||
| Return on equity | — | −37.6% | −12.2% |
| Return on tangible equity | — | −17.1% | −12.8% |
| Piotroski F-score | — | 3 | 4 |
| Altman Z'' | 2.2 | 15.0 | 3.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$44.5M
5 insiders
Of sales under plans
29%
$12.7M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Septerna, Inc. · SEPN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $44.14 a share, the company is worth $2.0B.
Source: SEC EDGAR XBRL filings (CIK 0001984086). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.